key: cord-0957352-42h6uj3a
authors: Kwok, Kin On; Lai, Florence; Wei, Wan In; Wong, Samuel Yeung Shan; Tang, Julian W.T.
title: Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries
date: 2020-03-21
journal: J Infect
DOI: 10.1016/j.jinf.2020.03.027
sha: 86d5a78f9bd6e91c6593e2af0f0aa8dbe0f36e58
doc_id: 957352
cord_uid: 42h6uj3a

nan

Previous workers have attempted to predict the cumulative number of cases of Coronavirus Disease 2019 (COVID-19) in China. 1 However, since then, the epidemic has rapidly evolved into a pandemic affecting multiple countries worlwide. 2 There have been serious debates about how to react to the spread of this disease, particularly by European countries, such as Italy, Spain, Germany, France and the UK, e.g. from closing schools and universities to locking down entire cities and countries. An alternative strategy would be to allow the causal virus (SARS-CoV-2) to spread to increase the population herd immunity, but at the same time protecting the elderly and those with multiple comorbidities, who are the most vulnerable to this virus. 3 Before initiating either of these strategies, we need to estimate the basic reproductive number (R 0 ), or the more 'real-life' effective reproductive number (R t ) for a given population. R 0 is the number of secondary cases generated by the presence of one infected individual in an otherwise fully susceptible, well-mixed population. R t is a more practical real-life version of this, which uses real-life data (from diagnostic testing and/or clinical surveillance) to estimate the reproductive number for an ongoing epidemic.

For this anaylsis, we will estimate R t , and we can do this by applying the exponential growth method, 4 using data on the daily number of new COVID-19 cases, together with a recent estimate of the serial interval (mean = 4.7 days, standard deviation = 2.9 days), 5 at a 0.05 significance level, with the mathematical software R (v3.6.1.). Table 1 Estimates of SARS-CoV-2 effective reproduction number (R t ) of 32 study countries (as of 13 March 2020, 7 ), and the minimum proportion (Pcrit, as% of population) needed to have recovered from COVID-19 with subsequent immunity, to halt the epidemic in that population.

Estimates of effective reproduction number (R t ) (95% CI), ( n = 32)

Minimum proportion (%) of total population required to recover from COVID-19 to confer immunity (P crit ) Using these values of R t , we can then calculate the minimum ('critical') level of population immunity, P crit , acquired via vaccination or naturally-induced (i.e. after recovery from COVID-19), to halt the spread of infection in that population, using the formula: P crit = 1-(1/R t ). So, for example, if the value of R t = 3 then P crit = 0.67, i.e. at least two-thirds of the population need to be immune. 6 As of 13 March 2020, there were 32 countries outside China with over 100 COVID-19 cases. 7 The seven countries with the highest number of infections were: the United States ( n = 2294), France ( n = 3671), Germany ( n = 3675), Spain ( n = 5232), Korea ( n = 8086), Iran ( n = 11,364) and Italy ( n = 17,660). The number of confirmed cases in the other 25 countries were less than 1200 ( Table 1 ) .

Exploring these parameters and their implications further, the difference between R 0 and R t is related to the proportion of individuals that are already immune (either by vaccination or natural infection) to that pathogen in that population. So another way of calculating R t for a pathogen in a given population is by multiplying R 0 by the proportion of that population that is non-immune (i.e. susceptible) to that pathogen. 6 Hence, R 0 will only equal R t when there are no immune individuals in the population (i.e. when all are susceptible). This means that any partial, pre-existing immunity to the infecting agent can reduce the number of expected secondary cases arising.

Although SARS-CoV-2 is a new coronavirus, one source of possible partial immunity to is some possible antibody cross-reactivity and partial immunity from previous infections with the common seasonal coronaviruses (OC43, 229E, NL63, HKU1) that have been circulating in human populations for decades, as was noted for SARS-CoV. 8 This could also be the case for SARS-CoV-2 and might explain why some individuals (perhaps those who have recently https://doi.org/10.1016/j.jinf.2020.03.027 0163-4453/© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. recovered from a seasonal coronavirus infection) have milder or asymptomatic infections. 9 Finally, returning to the concept of enhancing herd immunity to control the COVID-19 epidemic, given that the case fatality rate (CFR) of COVID-19 can be anything between 0.25-3.0% of a country's population, 10 the estimated number of people who could potentially die from COVID-19, whilst the population reaches the P crit herd immunity level, may be difficult to accept. 3 

Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in China by Boltzmann function-based regression analyses

COVID-19 situation in the WHO European Region . World Health Organization

Coronavirus: some scientists say UK virus strategy is 'risking lives

How generation intervals shape the relationship between growth rates and reproductive numbers

Serial interval of novel coronavirus (COVID-19) infections

RM Infectious Diseases of Humans: Dynamics and Control

COVID-19 update (39): global, more countries, stability, mitigation impact . WHO; 14

Serological assays for emerging coronaviruses: challenges and pitfalls

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Case-Fatality risk estimates for COVID-19 calculated by using a lag time for fatality